UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) October 2, 2006
Neurologix, Inc.
(Exact Name of Registrant as Specified in Charter)
Commission File Number: 000-13347
|
Delaware |
|
06-1582875 |
|
(State or other Jurisdiction of Incorporation) |
|
(I.R.S. Employer Identification No.) |
One Bridge Plaza, Fort Lee, New Jersey 07024
(Address of Principal Executive Offices)
(Zip Code)
(201) 592-6451
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. |
Regulation F-D Disclosure |
On October 17, 2006, Dr. Matthew J. During, a consultant to the Company and a member of its scientific advisory board, will present updated clinical data from the Company's Phase I study for its Parkinson's product at the Annual Meeting of The Society for Neuroscience in Atlanta, Georgia. A copy of the presentation abstract is filed herewith as Exhibit 99.1.
The information, including the exhibit attached hereto, in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
|
(d) |
Exhibits |
|
|
99.1 |
Abstract to be presented on October 17, 2006 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 4, 2006
|
|
NEUROLOGIX, INC. | ||
|
|
| ||
|
|
By: |
/s/ Marc L. Panoff |
|
|
|
|
Marc L. Panoff | |
|
|
|
Chief Financial Officer, Secretary and Treasurer | |